http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2337397-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_01dc12661ed2d8a4ebb867417d1f7f9d |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D225-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-6561 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D211-60 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D225-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F5-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-6561 |
| filingDate | 2006-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2010-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6cfd2650c0c4b014760c5682be3f8385 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d690f70642acd06a39d50e8febe33eed http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3e3c29daf376e9f8adcf8a8363c41c4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d3857a6db63eb37fdad94fa8d14dc9b2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e6d8dbc7019bb472cf151bce1420e6c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5c074bbe4a8e0a88ee53539e9a02377d |
| publicationDate | 2010-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2337397-T3 |
| titleOfInvention | HYDROQUINONE ANSAMYCINS FOR TUMORS TREATMENT OF GASTROINTESTINAL STROMA. |
| abstract | Use of a hydroquinone ansamycin compound represented by formula 1: ** (See formula) ** in which, independently for each presence: W is oxygen or sulfur; Q is oxygen, NR, N (acyl) or a bond; X- is a conjugate base of a pharmaceutically acceptable acid; R is selected for each presence, independently, from the group consisting of hydrogen, alkyl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroaryl and heteroarylalkyl; R1 is hydroxy, alkoxy, -OC (O) R8, -OC (O) OR9, -OC (O) NR10R11, -OSO2R12, -OC (O) NHSO2NR13R14, -NR13R14, or halide; and R2 is hydrogen, alkyl or arylalalkyl; or R1 and R2 together with the carbon to which they are attached represent -C (O =) -, -C (C = N-OR) -, - (C = N-NHR) -, or - (C = NR) - ; R3 and R4 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroaryl, heteroarylalkyl, and - [(CR2) p] -R16; or R3 together with R4 represent an optionally substituted 4-8 membered heterocyclic ring; R5 is selected from the group consisting of H, alkyl, arylalkyl, and a group having the formula 1a: ** (See formula) ** in which R17 is independently selected from the group consisting of hydrogen, halide, hydroxyl, alkoxy , aryloxy, acyloxy, amino, alkylamino, arylamino, acylamino, arylalkyl amino, nitro, acylthio, carboxamide, carboxyl, nitrile, -COR18, -CO2R18, -N (R18) CO2R19, -OC (O) N (R18) (R19) , -N (R18) SO2R19, -N (R18) C (O) N (R18) (R19) and -CH2O-heterocyclyl; R6 and R7 are both hydrogen; or R6 and R7 together form a bond; R8 is hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroaryl, heteroarylalkyl or - [(CR2) p] -R16; R9 is alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroaryl, heteroarylalkyl or - [(CR2) p] -R16; R10 and R11 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroaryl, heteroarylalkyl and - [(CR2) p] -R16; or R10 and R11, together with the nitrogen to which they are attached represent an optionally substituted 4-8 membered heterocyclic ring; R12 is alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroaryl, heteroarylalkyl or - [(CR2) p] -R16; R13 and R14 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroaryl, heteroarylalkyl and - [(CR2) p] -R16; or R13 and R14 together with the nitrogen to which they are attached represent an optionally substituted 4-8 membered heterocyclic ring; R16, for each presence, is independently selected from the group consisting of hydrogen, hydroxyl, acylamino, -N (R18) COR19, -N (R18) C (O) OR19, -N (R18) SO2 (R19), -CON (R18) (R19), -OC (O) N (R18) (R19), -SO2N (R18) (R19), -N (R18) (R19), -OC (O) OR18, -COOR18, -C (O) N (OH) (R18), -OS (O) 2OR18, -S (O2) OR18, -OP (O) (OR18) (OR19), -N (R18) P (O) (OR18) ( OR19) and -P (O) (OR18) (OR19); p is 1, 2, 3, 4, 5 or 6; R18, for each presence, is independently selected from the group consisting of hydrogen, alkyl, aryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroaryl and heteroarylalkyl; R19 is independently selected for each presence from the group consisting of hydrogen, alkyl, aryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroaryl and heteroarylalkyl; or R18 together with R19 represent an optionally substituted 5-8 member ring; R20, R21, R22, R24 and R25 are, for each presence, independently, alkyl; R23 is alkyl, -CH2OH, -CHO, -COOR18 or -CH (OR18) 2; R26 and R27, for each presence, are independently selected from the group consisting of hydrogen, alkyl, aryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroaryl and heteroarylalkyl; and the absolute stereochemistry at a stereogenic center of formula 1 may be R or S or a mixture of both and the stereochemistry of a double bond may be E or Z or a mixture of both; in the manufacture of a medicament for use in the treatment of one several gastrointestinal stromal tumors in a mammal. |
| priorityDate | 2005-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 360.